

Erratum

Author index

Volume 29 (1996)

The Publisher regrets that the Author index published in Volume 29 contained numerous errors. The corrected index is printed below.

- Andreoni, M., see Jacobsen, H. 29, 95
 Andreoni, M., see Vella, S. 29, 91
 Anné, J., see Esté, J.A. 29, 297
 Anné, J., see De Vreese, K. 29, 209
- Bahlman, W., Innovative combination clinical trial designs/patient compliance: A community perspective 29, 115
 Baldoni, J., see Black, P.L. 29, 175
 Barney, S., see Black, P.L. 29, 175
 Baruch, A., see Collier, A.C. 29, 99
 Bassett, R., see Collier, A.C. 29, 99
 Benoit, S., see McLaren, C. 29, 119
 Biron, F., F. Lucht, D. Peyramond, A. Fresard, T. Vallet, F. Nugier, J. Grange, S. Malley, F. Hamed-Sangsari, J. Villa, Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals 29, 111
 Black, P.L., M.A. Ussery, S. Barney, R. Wittrock, P. DeMarsh, G.B. Dreyer, S.R. Petteway Jr., P. DalMonte, J. Baldoni, D.M. Lambert, Effects of SKF 108922, an HIV-1 protease inhibitor, on retrovirus replication in mice 29, 175
 Blum, M.R., see St. Clair, M.H. 29, 53
 Boucher, C.A.B., see de Jong, M.D. 29, 5
 Bridger, G., see Esté, J.A. 29, 297
 Bridger, G.J., see De Vreese, K. 29, 209
 Bruggeman, C.A., see Stals, F.S. 29, 61
 Bu, M., see Turpin, J.A. 29, 269
 Buckheit Jr., R.W., see Turpin, J.A. 29, 269
 Buier, R.M., see Gwaltney Jr., J.M. 29, 287
- Cirelli, R., K. Herne, M. McCrary, P. Lee, S.K. Tying, Famciclovir: review of clinical efficacy and safety 29, 141
 Clanton, D., see Turpin, J.A. 29, 269
 Clark, J.M., see Yang, H. 29, 233
 Colacino, J.M., Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU) 29, 125
- Collier, A.C., R.W. Coombs, D.A. Schoenfeld, R. Bassett, A. Baruch, L. Corey, Combination therapy with zidovudine, didanosine and saquinavir 29, 99
 Conte, M.P., see Marchetti, M. 29, 221
 Coombs, R.W., see Collier, A.C. 29, 99
 Coombs, R.W., see Reichelderfer, P.S. 29, 83
 Corey, L., see Collier, A.C. 29, 99
 Cundy, K.C., see Wachsmann, M. 29, 153
- Daibata, M., E.-M. Enzinger, J.E. Monroe, R.E. Kilkuskie, A.K. Field, C. Mulder, Antisense oligodeoxynucleotides against the BZLF1 transcript inhibit induction of productive Epstein-Barr virus replication 29, 243
 DalMonte, P., see Black, P.L. 29, 175
 De Clercq, E., see De Vreese, K. 29, 209
 De Clercq, E., see Esté, J.A. 29, 297
 De Clercq, E., see Jashés, M. 29, 309
 de Jong, M.D., C.A.B. Boucher, G.J. Galasso, M.S. Hirsch, E.R. Kern, J.M.A. Lange, D.D. Richman, Consensus symposium on combined antiviral therapy 29, 5
 De Vreese, K., see Esté, J.A. 29, 297
 De Vreese, K., D. Reyman, P. Griffin, A. Steinkasserer, G. Werner, G.J. Bridger, J. Esté, W. James, G.W. Henson, J. Desmyter, J. Anné, E. De Clercq, The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding 29, 209
 DeMarsh, P., see Black, P.L. 29, 175
 Desmyter, J., see De Vreese, K. 29, 209
 Desmyter, J., see Esté, J.A. 29, 297
 Drain, R.L., see Yang, H. 29, 233
 Dreyer, G.B., see Black, P.L. 29, 175
 Duncan, I., see Vella, S. 29, 91
 Duncan, I.B., see Jacobsen, H. 29, 95
 Dusheiko, G.M., Summary: antiviral treatment of hepatitis C virus 29, 77

- Elkins, M., see McLaren, C. 29, 119
- Enzinger, E.-M., see Daibata., M. 29, 243
- Ercoli, L., see Vella, S. 29, 91
- Esté, J., see De Vreese, K. 29, 209
- Esté, J.A., K. De Vreese, M. Witvrouw, J.-C. Schmit, A.-M. Vandamme, J. Anné, J. Desmyter, G.W. Henson, G. Bridger, E. De Clercq, Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. 29, 261
- Faraj, A., R.F. Schinazi, M.-Y. Xie, G. Gosselin, C. Perigaud, J.-L. Imbach, J.-P. Sommadossi, Selective protection of toxicity of 2',3'-dideoxypyrimidine nucleoside analogs by β -D-uridine in human granulocyte-macrophage progenitor cells 29, 261
- Field, A.K., see Daibata., M. 29, 243
- Fisher, P.E., see Wachsman, M. 29, 153
- Franco, C.A., see Yang, H. 29, 233
- Fresard, A., see Biron, F. 29, 111
- Galasso, G.J., see de Jong, M.D. 29, 5
- Galluzzo, C., see Vella, S. 29, 91
- Garaci, E., see Pica, F. 29, 187
- Ghanem, A.-H., see Patel, P.J. 29, 279
- Giannini, G., see Vella, S. 29, 91
- Gnann Jr, J.W., see Whitley, R.J. 29, 67
- González, M., see Jashés, M. 29, 309
- Gorton, L., see Saravolac, E.G. 29, 199
- Gosselin, G., see Faraj, A. 29, 261
- Graham, L., see Turpin, J.A. 29, 269
- Grange, J., see Biron, F. 29, 111
- Griffin, P., see De Vreese, K. 29, 209
- Gwaltney Jr., J.M., R.M. Buier, J.L. Rogers, The influence of signal variation, bias, noise and effect size on statistical significance in treatment studies of the common cold 29, 287
- Haenggi, M., see Jacobsen, H. 29, 95
- Hamed-Sangsari, F., see Biron, F. 29, 111
- Haraguchi, Y., see Ikeda, R. 29, 163
- Hayden, F.G., Combination antiviral therapy for respiratory virus infections 29, 45
- Henson, G.W., see Esté, J.A. 29, 297
- Henson, G.W., see De Vreese, K. 29, 209
- Herne, K., see Cirelli, R. 29, 141
- Higuchi, W.I., see Patel, P.J. 29, 279
- Hirsch, M.S., see de Jong, M.D. 29, 5
- Hirschel, B., see Perrin, L. 29, 87
- Hoshino, H., see Ikeda, R. 29, 163
- Ikeda, R., Y. Haraguchi, Y. Ikeda, S. Kondo, T. Takeuchi, H. Hoshino, Inhibition of human immunodeficiency virus type 1 infectivity by a new amine bellenamine 29, 163
- Ikeda, Y., see Ikeda, R. 29, 163
- Imbach, J.-L., see Faraj, A. 29, 261
- Jabs, D.A., Design of clinical trials for drug combinations: cytomegalovirus retinitis — foscarnet and ganciclovir. The CMV retinitis retreatment trial 29, 69
- Jacobsen, H., see Vella, S. 29, 91
- Jacobsen, H., M. Haenggi, M. Ott, I.B. Duncan, M. Andreoni, S. Vella, J. Mous, Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials 29, 95
- James, W., see De Vreese, K. 29, 209
- Jashés, M., M. González, M. López-Lastra, E. De Clercq, A. Sandino, Inhibitors of infectious pancreatic necrosis virus (IPNV) replication 29, 309
- Jaffe, H.S., see Wachsman, M. 29, 153
- Johnson, V.A., Combination therapy for HIV-1 infection—overview: preclinical and clinical analysis of antiretroviral combinations 29, 35
- Kern, E.R., see de Jong, M.D. 29, 5
- Kern, E.R., see Patel, P.J. 29, 279
- Kern, E.R., Role of animal models in selecting antiviral combinations for clinical studies 29, 57
- Kern, E.R., D.D. Richman, Foreword. Consensus symposium on combined antiviral therapy 29, 3
- Kilkuskie, R.E., see Daibata., M. 29, 243
- Kloover, J.S., see Stals, F.S. 29, 61
- Kondo, S., see Ikeda, R. 29, 163
- Korba, B.E., In vitro evaluation of combination therapies against hepatitis B virus replication 29, 49
- Kournikakis, B., see Saravolac, E.G. 29, 199
- Lambert, D.M., see Black, P.L. 29, 175
- Lange, J.M.A., see de Jong, M.D. 29, 5
- Lee, P., see Cirelli, R. 29, 141
- Lietman, P.S., see Wachsman, M. 29, 153
- Lietman, P.S., Overview: Issues concerning the pharmacology of multiple drug regimens 29, 65
- Longhi, C., see Marchetti, M. 29, 221
- López-Lastra, M., see Jashés, M. 29, 309
- Lucht, F., see Biron, F. 29, 111
- Malley, S., see Biron, F. 29, 111
- Marchetti, M., C. Longhi, M.P. Conte, S. Pisani, P. Valenti, L. Seganti, Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells 29, 221
- McCrary, M., see Cirelli, R. 29, 141
- McLaren, C., M. Elkins, M. Salgo, M. Myers, S. Benoit, M. Warburg, Inter-Company Collaboration for AIDS Drug Development: perspective on combination studies 29, 119
- Millard, J., see St. Clair, M.H. 29, 53
- Monroe, J.E., see Daibata., M. 29, 243
- Mous, J., see Jacobsen, H. 29, 95
- Mulder, C., see Daibata., M. 29, 243
- Myers, M., see McLaren, C. 29, 119
- Nugier, F., see Biron, F. 29, 111
- Ott, M., see Jacobsen, H. 29, 95
- Painter, G., see St. Clair, M.H. 29, 53
- Palamara, A., see Pica, F. 29, 187
- Parry, N., see St. Clair, M.H. 29, 53

- Pastelak, A., see Wachsmann, M. 29, 153
- Patel, P.J., A.-H. Ghanem, W.I. Higuchi, V. Srinivasan, E.R. Kern, Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept 29, 297
- Perigaud, C., see Faraj, A. 29, 261
- Perrin, L., B. Hirschel, Combination therapy in primary HIV infection 29, 87
- Petteway, Jr., S.R., see Black, P.L. 29, 175
- Petty, B.G., see Wachsmann, M. 29, 153
- Peyramond, D., see Biron, F. 29, 111
- Pica, F., A. Rossi, N. Santirocco, A. Palamara, E. Garaci, M.G. Santoro, Effect of combined α IFN and prostaglandin A₁ treatment on vesicular stomatitis virus replication and heat shock protein synthesis in epithelial cells 29, 187
- Pirillo, M.F., see Vella, S. 29, 91
- Pisani, S., see Marchetti, M. 29, 221
- Pollard, R.B., CMV retinitis: ganciclovir/monoclonal antibody 29, 73
- Pollard, R.B., D4T nucleoside combinations for HIV 29, 101
- Reichelderfer, P.S., R.W. Coombs, Cartesian coordinate analysis of viral burden and CD4+ cell count in HIV disease: implications for clinical trial design and analysis 29, 83
- Reymen, D., see De Vreese, K. 29, 209
- Rice, W.G., see Turpin, J.A. 29, 269
- Richman, D.D., The implications of drug resistance for strategies of combination antiviral chemotherapy 29, 31
- Richman, D.D., see Jong, M.D.d. 29, 5
- Richman, D.D., see Kern, E.R. 29, 3
- Rogers, J.L., see Gwaltney Jr., J.M. 29, 287
- Rooney, J., see St. Clair, M.H. 29, 53
- Rossi, A., see Pica, F. 29, 187
- Sadler, B.M., see St. Clair, M.H. 29, 53
- Salgo, M., see McLaren, C. 29, 119
- Sandino, A., see Jashés, M. 29, 309
- Santirocco, N., see Pica, F. 29, 187
- Santoro, M.G., see Pica, F. 29, 187
- Saravolac, E.G., B. Kournikakis, L. Gorton, J.P. Wong, Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon- γ 29, 199
- Sarmati, L., see Vella, S. 29, 91
- Schaeffer, C.A., see Turpin, J.A. 29, 269
- Schinazi, R.F., see Faraj, A. 29, 261
- Schmit, J.-C., see Esté, J.A. 29, 297
- Schoenfeld, D.A., see Collier, A.C. 29, 99
- Seganti, L., see Marchetti, M. 29, 221
- Shipman, Jr., C., Analysis of drug-drug interactions: an overview 29, 41
- Sneller, M.C., Consensus symposium on combined antiviral therapy; Overview of interferon and IL-2 combinations for the treatment of HIV infection 29, 105
- Sommadossi, J.-P., see Faraj, A. 29, 261
- Soong, S.-j., see Whitley, R.J. 29, 67
- Srinivasan, V., see Patel, P.J. 29, 279
- St. Clair, M.H., J. Millard, J. Rooney, M. Tisdale, N. Parry, B.M. Sadler, M.R. Blum, G. Painter, In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents 29, 53
- Stals, F.S., S.S. Wagenaar, J.S. Kloover, W.Y.R. Vanagt, C.A. Bruggeman, Combinations of ganciclovir and antibody for experimental CMV infections 29, 61
- Steinkasserer, A., see De Vreese, K. 29, 209
- Takeuchi, T., see Ikeda, R. 29, 163
- Tisdale, M., see St. Clair, M.H. 29, 53
- Turpin, J.A., C.A. Schaeffer, M. Bu, L. Graham, R.W. Buckheit Jr., D. Clanton, W.G. Rice, Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor 29, 269
- Tyring, S.K., see Cirelli, R. 29, 141
- Ussery, M.A., see Black, P.L. 29, 175
- Valenti, P., see Marchetti, M. 29, 221
- Vallet, T., see Biron, F. 29, 111
- Vanagt, W.Y.R., see Stals, F.S. 29, 61
- Vandamme, A.-M., see Esté, J.A. 29, 297
- Vella, S., see Jacobsen, H. 29, 95
- Vella, S., C. Galluzzo, G. Giannini, M.F. Pirillo, I. Duncan, H. Jacobsen, M. Andreoni, L. Sarmati, L. Ercoli, Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity 29, 91
- Vila, J., see Biron, F. 29, 111
- Wachsmann, M., B.G. Petty, K.C. Cundy, H.S. Jaffe, P.E. Fisher, A. Pastelak, P.S. Lietman, Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects 29, 153
- Wagenaar, S.S., see Stals, F.S. 29, 61
- Warburg, M., see McLaren, C. 29, 119
- Weiss, H.L., see Whitley, R.J. 29, 67
- Werner, G., see De Vreese, K. 29, 209
- Whitley, R.J., J.W. Gnann Jr, H.L. Weiss, S.-j. Soong, Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host 29, 67
- Wittrock, R., see Black, P.L. 29, 175
- Witvrouw, M., see Esté, J.A. 29, 297
- Wong, J.P., see Saravolac, E.G. 29, 199
- Xie, M.-Y., see Faraj, A. 29, 261
- Yang, H., R.L. Drain, C.A. Franco, J.M. Clark, Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice 29, 233